http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20100017510-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_244630447017dc0b8a917a82d7ad0036 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-222 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-226 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-56 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557 |
| filingDate | 2008-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b3b8bffa4c300434d974ba2e620e5a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93a8298edee671c981125107d43fe2d4 |
| publicationDate | 2010-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20100017510-A |
| titleOfInvention | How to measure platelet reactivity in individuals treated with drug-eluting stents |
| abstract | Methods of measuring platelet reactivity inhibition in an individual treated with drug-eluting stents (DES) are provided. First, blood samples are taken from individuals treated with DES and P2Y12 antagonists. The blood sample is then mixed with particles comprising the attached GPIIb / IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for aggregation of the particles and the platelet-mediated aggregation in the mixture is assessed. If no aggregation is seen or reduced, the subject treated with DES has reduced platelet reactivity. In addition, the P2Y12 receptor, comprising a GPIIb / IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1), an anticoagulant, and a buffer added to the particles to maintain blood at conditions suitable for platelet aggregation Kits for measuring inhibition of platelet aggregation by antagonists are provided. |
| priorityDate | 2007-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 186.